Eric P Hoffman

List of Publications by Year in Descending Order

439 papers	27,460 citations	78 h-index	154 g-index
478 ext. papers	30,386 ext. citations	7.4 avg, IF	6.63 L-index

#	Paper	IF	Citations
439	Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.. *JAMA Network Open*, **2022**, 5, e2144178	10.4	3
438	A mouse model of inherited choline kinase β deficiency presents with specific cardiac abnormalities and a predisposition to arrhythmia.. *Journal of Biological Chemistry*, **2022**, 101716	5.4	1
437	Acute serum protein and cytokine response of single dose of prednisone in adult volunteers.. *Steroids*, **2022**, 178, 108953	2.8	0
436	Mechanism of action and therapeutic route for a muscular dystrophy caused by a genetic defect in lipid metabolism.. *Nature Communications*, **2022**, 13, 1559	17.4	1
435	Genetic modifiers of upper limb function in Duchenne muscular dystrophy.. *Journal of Neurology*, **2022**, 1	5.5	1
434	Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy. *Journal of Neuromuscular Diseases*, **2022**, 1-9	5	4
433	A Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
432	Concerns Regarding Therapeutic Implications of Very Low-Level Dystrophin. *Annals of Neurology*, **2021**, 90, 176	9.4	1
431	Elevation of fast but not slow troponin I in the circulation of patients with Becker and Duchenne muscular dystrophy. *Muscle and Nerve*, **2021**, 64, 43-49	3.4	5
430	Human muscle stem cells are refractory to aging. *Aging Cell*, **2021**, 20, e13411	9.9	9
429	Exon-Skipping in Duchenne Muscular Dystrophy. *Journal of Neuromuscular Diseases*, **2021**, 8, S343-S358	5	4
428	The Influence of Metabolic Syndrome Risk Factors on Carotid Intima Media Thickness in Children. *Global Pediatric Health*, **2021**, 8, 2333794X20987453	1.2	1
427	Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice. *PLoS ONE*, **2021**, 16, e0246507	3.7	4
426	Blunted circadian cortisol in children is associated with poor cardiovascular health and may reflect circadian misalignment. *Psychoneuroendocrinology*, **2021**, 129, 105252	5	2
425	Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy. *Journal of Neuromuscular Diseases*, **2021**, 8, S369-S381	5	
424	Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy. *Journal of Clinical Pharmacology*, **2020**, 60, 1385-1396	2.9	2
423	Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. *JAMA Neurology*, **2020**, 77, 982-991	17.2	71

422	Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys. *Human Molecular Genetics*, **2020**, 29, 2481-2495	5.6	7
421	The discovery of dystrophin, the protein product of the Duchenne muscular dystrophy gene. *FEBS Journal*, **2020**, 287, 3879-3887	5.7	11
420	MicroRNA Profiling in Adipose Before and After Weight Loss Highlights the Role of miR-223-3p and the NLRP3 Inflammasome. *Obesity*, **2020**, 28, 570-580	8	5
419	Muscle Weakness in Myositis: MicroRNA-Mediated Dystrophin Reduction in a Myositis Mouse Model and Human Muscle Biopsies. *Arthritis and Rheumatology*, **2020**, 72, 1170-1183	9.5	12
418	Genetic modifiers of respiratory function in Duchenne muscular dystrophy. *Annals of Clinical and Translational Neurology*, **2020**, 7, 786-798	5.3	14
417	Pharmacotherapy of Duchenne Muscular Dystrophy. *Handbook of Experimental Pharmacology*, **2020**, 261, 25-37	3.2	11
416	Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies. *Acta Myologica*, **2020**, 39, 179-186	1.6	4
415	Absolute quantification of dystrophin protein in human muscle biopsies using parallel reaction monitoring (PRM). *Journal of Mass Spectrometry*, **2020**, 55, e4437	2.2	8
414	TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy. *European Journal of Human Genetics*, **2020**, 28, 815-825	5.3	10
413	A long-read RNA-seq approach to identify novel transcripts of very large genes. *Genome Research*, **2020**, 30, 885-897	9.7	9
412	Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. *PLoS Medicine*, **2020**, 17, e1003222	11.6	17
411	Novel mutation identification and copy number variant detection via exome sequencing in congenital muscular dystrophy. *Molecular Genetics & Genomic Medicine*, **2020**, 8, e1387	2.3	1
410	Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 24285-24293	11.5	12
409	Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study **2020**, 17, e1003222		
408	Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study **2020**, 17, e1003222		
407	Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study **2020**, 17, e1003222		
406	Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study **2020**, 17, e1003222		
405	Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study **2020**, 17, e1003222		

404	Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study **2020**, 17, e1003222		
403	Biomarkers for Muscle Disease Gene Therapy **2019**, 239-252		
402	Asymmetric independence modeling identifies novel gene-environment interactions. *Scientific Reports*, **2019**, 9, 2455	4.9	
401	Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice. *Journal of Pathology*, **2019**, 248, 339-351	9.4	12
400	Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy. *Journal of Clinical Pharmacology*, **2019**, 59, 979-988	2.9	8
399	Orthogonal analysis of dystrophin protein and mRNA as a surrogate outcome for drug development. *Biomarkers in Medicine*, **2019**, 13, 1209-1225	2.3	5
398	Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy. *Scientific Reports*, **2019**, 9, 12167	4.9	22
397	Discovery of potential urine-accessible metabolite biomarkers associated with muscle disease and corticosteroid response in the mdx mouse model for Duchenne. *PLoS ONE*, **2019**, 14, e0219507	3.7	4
396	Influence of □adrenergic receptor genotype on risk of nocturnal ventilation in patients with Duchenne muscular dystrophy. *Respiratory Research*, **2019**, 20, 221	7.3	2
395	Developmental Pharmacodynamics and Modeling in Pediatric Drug Development. *Journal of Clinical Pharmacology*, **2019**, 59 Suppl 1, S87-S94	2.9	7
394	Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. *Life Science Alliance*, **2019**, 2,	5.8	28
393	Genome-Wide Association Studies in Muscle Physiology and Disease **2019**, 9-30		0
392	Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. *Neurology*, **2019**, 93, e1312-e1323	6.5	38
391	Congenital Titinopathy: Comprehensive characterization and pathogenic insights. *Annals of Neurology*, **2018**, 83, 1105-1124	9.4	59
390	A genetic variant in IL-15R□correlates with physical activity among European-American adults. *Molecular Genetics & Genomic Medicine*, **2018**, 6, 401-408	2.3	6
389	Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. *Steroids*, **2018**, 134, 43-52	2.8	37
388	Expression of macrophage genes within skeletal muscle correlates inversely with adiposity and insulin resistance in humans. *Applied Physiology, Nutrition and Metabolism*, **2018**, 43, 187-193	3	5
387	Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone. *Physiological Genomics*, **2018**, 50, 735-745	3.6	19

386	Genetic Variation in Acid Ceramidase Predicts Non-completion of an Exercise Intervention. *Frontiers in Physiology*, **2018**, 9, 781	4.6	5
385	Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DNHS). *PLOS Currents*, **2018**, 10,		4
384	Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. *Lancet, The*, **2018**, 391, 451-461	40	181
383	PCB exposure and potential future cancer incidence in Slovak children: an assessment from molecular finger printing by Ingenuity Pathway Analysis (IPA) derived from experimental and epidemiological investigations. *Environmental Science and Pollution Research*, **2018**, 25, 16493-16507	5.1	18
382	Mechanisms of allelic and clinical heterogeneity of lamin A/C phenotypes. *Physiological Genomics*, **2018**, 50, 694-704	3.6	6
381	Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. *Steroids*, **2018**, 140, 159-166	2.8	15
380	Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. *Pharmacological Research*, **2018**, 136, 140-150	10.2	47
379	Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit. *Molecular Therapy*, **2018**, 26, 2231-2242	11.7	33
378	Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy. *Nature Communications* , **2017**, 8, 14143	17.4	32
377	Genetic characterization of physical activity behaviours in university students enrolled in kinesiology degree programs. *Applied Physiology, Nutrition and Metabolism*, **2017**, 42, 278-284	3	3
376	miRTarVis+: Web-based interactive visual analytics tool for microRNA target predictions. *Methods*, **2017**, 124, 78-88	4.6	9
375	Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle. *Nature Communications*, **2017**, 8, 941	17.4	28
374	The Relationship between Coronary Artery Disease Risk Factors and Carotid Intima-Media Thickness in Children. *Journal of Pediatrics*, **2017**, 190, 38-42	3.6	7
373	Osteopontin is linked with AKT, FoxO1, and myostatin in skeletal muscle cells. *Muscle and Nerve*, **2017**, 56, 1119-1127	3.4	12
372	Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. *Nature Communications*, **2017**, 8, 80	17.4	88
371	The angiotensin-converting enzyme insertion/deletion polymorphism rs4340 associates with habitual physical activity among European American adults. *Molecular Genetics & Genomic Medicine*, **2017**, 5, 524-530	2.3	5
370	African-American esophageal squamous cell carcinoma expression profile reveals dysregulation of stress response and detox networks. *BMC Cancer*, **2017**, 17, 426	4.8	8
369	Novel Col12A1 variant expands the clinical picture of congenital myopathies with extracellular matrix defects. *Muscle and Nerve*, **2017**, 55, 277-281	3.4	20

368	Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease. *Clinical and Translational Gastroenterology* , **2016**, 7, e192	4.2	32
367	DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. *Neurology*, **2016**, 87, 401-9	6.5	68
366	Association Study of Exon Variants in the NF-B and TGF Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy. *American Journal of Human Genetics*, **2016**, 99, 1163-1171	11	42
365	Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. *Scientific Reports*, **2016**, 6, 31727	4.9	32
364	Laminopathies disrupt epigenomic developmental programs and cell fate. *Science Translational Medicine*, **2016**, 8, 335ra58	17.5	73
363	Clinical utility of serum biomarkers in Duchenne muscular dystrophy. *Clinical Proteomics*, **2016**, 13, 9	5	52
362	Diagnosis and etiology of congenital muscular dystrophy: We are halfway there. *Annals of Neurology*, **2016**, 80, 101-11	9.4	39
361	Somatic mosaicism due to a reversion variant causing hemi-atrophy: a novel variant of dystrophinopathy. *European Journal of Human Genetics*, **2016**, 24, 1511-4	5.3	4
360	Glucocorticoid Receptor (NR3C1) Variants Associate with the Muscle Strength and Size Response to Resistance Training. *PLoS ONE*, **2016**, 11, e0148112	3.7	7
359	Metataxonomic and Metagenomic Approaches vs. Culture-Based Techniques for Clinical Pathology. *Frontiers in Microbiology*, **2016**, 7, 484	5.7	58
358	Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. *PLoS ONE*, **2016**, 11, e0153461	3.7	17
357	Targeted Re-Sequencing Emulsion PCR Panel for Myopathies: Results in 94 Cases. *Journal of Neuromuscular Diseases*, **2016**, 3, 209-225	5	13
356	Pyruvate Dehydrogenase Phosphatase Regulatory Gene Expression Correlates with Exercise Training Insulin Sensitivity Changes. *Medicine and Science in Sports and Exercise*, **2016**, 48, 2387-2397	1.2	4
355	Mathematical modelling of transcriptional heterogeneity identifies novel markers and subpopulations in complex tissues. *Scientific Reports*, **2016**, 6, 18909	4.9	39
354	Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. *Rheumatology*, **2016**, 55, 1673-80	3.9	10
353	Salivary latent trait cortisol (LTC): Relation to lipids, blood pressure, and body composition in middle childhood. *Psychoneuroendocrinology*, **2016**, 71, 110-8	5	7
352	Homozygous mutation in Atlastin GTPase 1 causes recessive hereditary spastic paraplegia. *Journal of Human Genetics*, **2016**, 61, 571-3	4.3	6
351	Examination of Lifestyle Behaviors and Cardiometabolic Risk Factors in University Students Enrolled in Kinesiology Degree Programs. *Journal of Strength and Conditioning Research*, **2016**, 30, 1137-46	3.2	5

350	OPN-a induces muscle inflammation by increasing recruitment and activation of pro-inflammatory macrophages. *Experimental Physiology*, **2016**, 101, 1285-1300	2.4	17
349	An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss. *Genome Biology*, **2015**, 16, 8	18.3	159
348	Immune-mediated pathology in Duchenne muscular dystrophy. *Science Translational Medicine*, **2015**, 7, 299rv4	17.5	131
347	Dystrophinopathies **2015**, 1103-1111		2
346	Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 7153-8	11.5	172
345	Transcriptional profiling and biological pathway analysis of human equivalence PCB exposure in vitro: indicator of disease and disorder development in humans. *Environmental Research*, **2015**, 138, 202-16	7.9	14
344	Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. *Circulation*, **2015**, 131, 1590-8	16.7	173
343	Obesity-Related Genetic Variants and their Associations with Physical Activity. *Sports Medicine - Open*, **2015**, 1, 34	6.1	13
342	Global gene expression profiling in R155H knock-in murine model of VCP disease. *Clinical and Translational Science*, **2015**, 8, 8-16	4.9	2
341	Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. *Neurology*, **2015**, 85, 1048-55	6.5	108
340	The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse. *Toxicology Reports*, **2015**, 2, 838-849	4.8	22
339	KDDN: an open-source Cytoscape app for constructing differential dependency networks with significant rewiring. *Bioinformatics*, **2015**, 31, 287-9	7.2	16
338	miRTarVis: an interactive visual analysis tool for microRNA-mRNA expression profile data. *BMC Proceedings*, **2015**, 9, S2	2.3	50
337	TNF-□nduced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy. *Cell Reports*, **2015**, 12, 1678-90	10.6	50
336	Elusive sources of variability of dystrophin rescue by exon skipping. *Skeletal Muscle*, **2015**, 5, 44	5.1	22
335	The ACTN3 R577X Polymorphism Is Associated with Cardiometabolic Fitness in Healthy Young Adults. *PLoS ONE*, **2015**, 10, e0130644	3.7	23
334	Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study. *Annals of Neurology*, **2015**, 77, 684-96	9.4	76
333	Upregulated IL-1□n dysferlin-deficient muscle attenuates regeneration by blunting the response to pro-inflammatory macrophages. *Skeletal Muscle*, **2015**, 5, 24	5.1	17

332	Exome Sequencing Identifies DYNC1H1 Variant Associated With Vertebral Abnormality and Spinal Muscular Atrophy With Lower Extremity Predominance. *Pediatric Neurology*, **2015**, 52, 239-44	2.9	22
331	VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. *Cellular and Molecular Neurobiology*, **2015**, 35, 377-387	4.6	19
330	Recessive ACTA1 variant causes congenital muscular dystrophy with rigid spine. *European Journal of Human Genetics*, **2015**, 23, 883-6	5.3	16
329	Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy. *PLoS ONE*, **2015**, 10, e0141240	3.7	40
328	SLC30A8 nonsynonymous variant is associated with recovery following exercise and skeletal muscle size and strength. *Diabetes*, **2014**, 63, 363-8	0.9	19
327	Multi-omic integrated networks connect DNA methylation and miRNA with skeletal muscle plasticity to chronic exercise in Type 2 diabetic obesity. *Physiological Genomics*, **2014**, 46, 747-65	3.6	72
326	Single-molecule long-read 16S sequencing to characterize the lung microbiome from mechanically ventilated patients with suspected pneumonia. *Journal of Clinical Microbiology*, **2014**, 52, 3913-21	9.7	44
325	A rebirth for drisapersen in Duchenne muscular dystrophy?. *Lancet Neurology, The*, **2014**, 13, 963-5	24.1	5
324	Metabolite signatures of exercise training in human skeletal muscle relate to mitochondrial remodelling and cardiometabolic fitness. *Diabetologia*, **2014**, 57, 2282-95	10.3	88
323	Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy. *Journal of Cell Biology*, **2014**, 207, 139-58	7.3	80
322	Knowledge-fused differential dependency network models for detecting significant rewiring in biological networks. *BMC Systems Biology*, **2014**, 8, 87	3.5	23
321	Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. *Human Molecular Genetics*, **2014**, 23, 6458-69	5.6	85
320	Natural progression of childhood asthma symptoms and strong influence of sex and puberty. *Annals of the American Thoracic Society*, **2014**, 11, 939-44	4.7	65
319	Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. *ILAR Journal*, **2014**, 55, 119-49	1.7	39
318	Mitotic asynchrony induces transforming growth factor-1 secretion from airway epithelium. *American Journal of Respiratory Cell and Molecular Biology*, **2014**, 51, 363-9	5.7	12
317	Response to Comment on Sprouse et al. SLC30A8 nonsynonymous variant is associated with recovery following exercise and skeletal muscle size and strength. Diabetes 2014;63:363-368. *Diabetes*, **2014**, 63, e9-e10	0.9	2
316	Eccentric muscle challenge shows osteopontin polymorphism modulation of muscle damage. *Human Molecular Genetics*, **2014**, 23, 4043-50	5.6	16
315	Exon-skipping therapy: a roadblock, detour, or bump in the road?. *Science Translational Medicine*, **2014**, 6, 230fs14	17.5	29

314	Rhinovirus infection in young children is associated with elevated airway TSLP levels. *European Respiratory Journal*, **2014**, 44, 1075-8	13.6	32
313	Neck and waist circumference biomarkers of cardiovascular risk in a cohort of predominantly African-American college students: a preliminary study. *Journal of the Academy of Nutrition and Dietetics*, **2014**, 114, 107-16	3.9	21
312	Non-invasive MRI and spectroscopy of mdx mice reveal temporal changes in dystrophic muscle imaging and in energy deficits. *PLoS ONE*, **2014**, 9, e112477	3.7	20
311	The SORT1 risk allele is associated with exaggerated postprandial lipaemia in young adults (383.5). *FASEB Journal*, **2014**, 28, 383.5	0.9	
310	Molecular Diagnosis and Genetic Testing **2014**, 271-284		
309	ACTN3 genotype predicts metabolic, anthropometric and cardiovascular phenotypes in a young, healthy population (711.8). *FASEB Journal*, **2014**, 28, 711.8	0.9	
308	A novel mutation expands the genetic and clinical spectrum of MYH7-related myopathies. *Neuromuscular Disorders*, **2013**, 23, 432-6	2.9	30
307	Microarray analysis reveals novel features of the muscle aging process in men and women. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2013**, 68, 1035-44	6.4	38
306	Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of α-dystroglycan. *American Journal of Human Genetics*, **2013**, 93, 29-41	11	162
305	Sparing of the dystrophin-deficient cranial sartorius muscle is associated with classical and novel hypertrophy pathways in GRMD dogs. *American Journal of Pathology*, **2013**, 183, 1411-24	5.8	33
304	Impaired autophagy, chaperone expression, and protein synthesis in response to critical illness interventions in porcine skeletal muscle. *Physiological Genomics*, **2013**, 45, 477-86	3.6	24
303	Effect of the SORT1 low-density lipoprotein cholesterol locus is sex-specific in a fit, Canadian young-adult population. *Applied Physiology, Nutrition and Metabolism*, **2013**, 38, 188-93	3	8
302	VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 2241-2249	3.4	41
301	Effects of corticosteroids in the development of limb muscle weakness in a porcine intensive care unit model. *Physiological Genomics*, **2013**, 45, 312-20	3.6	9
300	Alterations in osteopontin modify muscle size in females in both humans and mice. *Medicine and Science in Sports and Exercise*, **2013**, 45, 1060-8	1.2	30
299	Highlights from the functional single nucleotide polymorphisms associated with human muscle size and strength or FAMuSS study. *BioMed Research International*, **2013**, 2013, 643575	3	18
298	Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse. *Molecular and Cellular Proteomics*, **2013**, 12, 1061-73	7.6	78
297	Short read (next-generation) sequencing: a tutorial with cardiomyopathy diagnostics as an exemplar. *Circulation: Cardiovascular Genetics*, **2013**, 6, 427-34		14

296	The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. *Muscle and Nerve*, **2013**, 48, 32-54	3.4	111
295	Differential gene expression reveals mitochondrial dysfunction in an imprinting center deletion mouse model of Prader-Willi syndrome. *Clinical and Translational Science*, **2013**, 6, 347-55	4.9	18
294	The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. *Muscle and Nerve*, **2013**, 48, 55-67	3.4	138
293	The effects of MyD88 deficiency on disease phenotype in dysferlin-deficient A/J mice: role of endogenous TLR ligands. *Journal of Pathology*, **2013**, 231, 199-209	9.4	18
292	VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. *EMBO Molecular Medicine*, **2013**, 5, 1569-85	12	117
291	Moderate-intensity aerobic training program improves insulin sensitivity and inflammatory markers in a pilot study of morbidly obese minority teens. *Pediatric Exercise Science*, **2013**, 25, 12-26	2	21
290	Status of Gene in PCB-exposed Population: A Quick Look. *International Journal of Human Genetics*, **2013**, 13, 27-32	1	8
289	VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice. *PLoS ONE*, **2013**, 8, e63871	3.7	20
288	The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice. *PLoS ONE*, **2013**, 8, e66617	3.7	3
287	Aging influences the expression of early response genes following acute resistance exercise in trained skeletal muscle. *FASEB Journal*, **2013**, 27, 710.3	0.9	
286	Asymptomatic African Americans with high-risk APOL1 genotypes have reduced urinary angiogenesis-promoting cytokines. *FASEB Journal*, **2013**, 27, lb474	0.9	
285	Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. *Discovery Medicine*, **2013**, 16, 233-9	2.5	43
284	Characterization of Transferrin Glycopeptide Structures in Human Cerebrospinal Fluid. *International Journal of Mass Spectrometry*, **2012**, 312, 97-106	1.9	15
283	Global gene profiling of VCP-associated inclusion body myopathy. *Clinical and Translational Science*, **2012**, 5, 226-34	4.9	8
282	Computational Analysis of Muscular Dystrophy Sub-types Using A Novel Integrative Scheme. *Neurocomputing*, **2012**, 92, 9-17	5.4	2
281	Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. *Mammalian Genome*, **2012**, 23, 85-108	3.2	117
280	Sphingosine-1-phosphate enhances satellite cell activation in dystrophic muscles through a S1PR2/STAT3 signaling pathway. *PLoS ONE*, **2012**, 7, e37218	3.7	55
279	TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle. *Journal of Pathology*, **2012**, 228, 251-9	9.4	20

278	Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. *Physical Medicine and Rehabilitation Clinics of North America*, **2012**, 23, 821-8	2.3	37
277	Differential gene expression and a functional analysis of PCB-exposed children: understanding disease and disorder development. *Environment International*, **2012**, 40, 143-154	12.9	36
276	Analysis of the toxicogenomic effects of exposure to persistent organic pollutants (POPs) in Slovakian girls: correlations between gene expression and disease risk. *Environment International*, **2012**, 39, 188-99	12.9	36
275	Genome-wide identification of significant aberrations in cancer genome. *BMC Genomics*, **2012**, 13, 342	4.5	27
274	Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. *Skeletal Muscle*, **2012**, 2, 16	5.1	64
273	Eps homology domain endosomal transport proteins differentially localize to the neuromuscular junction. *Skeletal Muscle*, **2012**, 2, 19	5.1	7
272	Genomics, intellectual disability, and autism. *New England Journal of Medicine*, **2012**, 366, 733-43	59.2	218
271	The paradox of muscle hypertrophy in muscular dystrophy. *Physical Medicine and Rehabilitation Clinics of North America*, **2012**, 23, 149-72, xii	2.3	67
270	Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. *PLoS ONE*, **2012**, 7, e34204	3.7	48
269	Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. *Nucleic Acid Therapeutics*, **2012**, 22, 306-15	4.8	66
268	Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. *Brain and Behavior*, **2012**, 2, 563-75	3.4	60
267	Endothelial Nitric Oxide Synthase (NOS3) +894 G>T Associates with Physical Activity and Muscle Performance among Young Adults. *ISRN Vascular Medicine*, **2012**, 2012, 1-7		3
266	Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 13763-8	11.5	118
265	9,11 modification of glucocorticoids dissociates nuclear factor-B inhibitory efficacy from glucocorticoid response element-associated side effects. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 343, 225-32	4.7	25
264	Resistance exercise training influences skeletal muscle immune activation: a microarray analysis. *Journal of Applied Physiology*, **2012**, 112, 443-53	3.7	68
263	Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. *Neurology*, **2012**, 79, 159-62	6.5	62
262	Microtubules underlie dysfunction in duchenne muscular dystrophy. *Science Signaling*, **2012**, 5, ra56	8.8	161
261	Variants of the ankyrin repeat domain 6 gene (ANKRD6) and muscle and physical activity phenotypes among European-derived American adults. *Journal of Strength and Conditioning Research*, **2012**, 26, 1740-8	3.2	12

260	Role of sepsis in the development of limb muscle weakness in a porcine intensive care unit model. *Physiological Genomics*, **2012**, 44, 865-77	3.6	13
259	Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry. *Journal of Bioanalysis & Biomedicine*, **2012**, Suppl 7,	1	27
258	Evolution and comparative genomics of subcellular specializations: EST sequencing of Torpedo electric organ. *Marine Genomics*, **2011**, 4, 33-40	1.9	6
257	Proteomic responses of skeletal and cardiac muscle to exercise. *Expert Review of Proteomics*, **2011**, 8, 361-77	4.2	55
256	Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy. *Methods in Molecular Biology*, **2011**, 709, 299-312	1.4	36
255	Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. *American Journal of Pathology*, **2011**, 179, 12-22	5.8	79
254	Global gene expression and Ingenuity biological functions analysis on PCBs 153 and 138 induced human PBMC in vitro reveals differential mode(s) of action in developing toxicities. *Environment International*, **2011**, 37, 838-57	12.9	25
253	MC4R variant is associated with BMI but not response to resistance training in young females. *Obesity*, **2011**, 19, 662-6	8	15
252	Non-invasive optical imaging of muscle pathology in mdx mice using cathepsin caged near-infrared imaging. *Molecular Imaging and Biology*, **2011**, 13, 462-470	3.8	25
251	Progression of volume load and muscular adaptation during resistance exercise. *European Journal of Applied Physiology*, **2011**, 111, 1063-71	3.4	38
250	AKT1 polymorphisms are associated with risk for metabolic syndrome. *Human Genetics*, **2011**, 129, 129-39	6.3	22
249	Characterization of the ZBTB42 gene in humans and mice. *Human Genetics*, **2011**, 129, 433-41	6.3	5
248	Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. *BMC Cardiovascular Disorders*, **2011**, 11, 20	2.3	52
247	Delayed inflammatory mRNA and protein expression after spinal cord injury. *Journal of Neuroinflammation*, **2011**, 8, 130	10.1	58
246	Integrated genomics and proteomics of the Torpedo californica electric organ: concordance with the mammalian neuromuscular junction. *Skeletal Muscle*, **2011**, 1, 20	5.1	13
245	Motif-guided sparse decomposition of gene expression data for regulatory module identification. *BMC Bioinformatics*, **2011**, 12, 82	3.6	13
244	Transcriptional deficits in oxidative phosphorylation with statin myopathy. *Muscle and Nerve*, **2011**, 44, 393-401	3.4	22
243	DDN: a caBIG analytical tool for differential network analysis. *Bioinformatics*, **2011**, 27, 1036-8	7.2	33

242	Asthmatic airway epithelium is intrinsically inflammatory and mitotically dyssynchronous. *American Journal of Respiratory Cell and Molecular Biology*, **2011**, 44, 863-9	5.7	60
241	The 1p13.3 LDL (C)-associated locus shows large effect sizes in young populations. *Pediatric Research*, **2011**, 69, 538-43	3.2	12
240	Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2011**, 16, 87-95	2.6	84
239	PUGSVM: a caBIG analytical tool for multiclass gene selection and predictive classification. *Bioinformatics*, **2011**, 27, 736-8	7.2	15
238	Mechanisms underlying the sparing of masticatory versus limb muscle function in an experimental critical illness model. *Physiological Genomics*, **2011**, 43, 1334-50	3.6	27
237	Asthmatic Bronchial Epithelium Is Intrinsically Inflammogenic, Mitotically Dyssynchronous, And Is Rescued By Glucocorticoids **2010**,		2
236	Characterizing the Extent of Human Genetic Variation for Performance-Related Traits **2010**, 33-45		3
235	Genetic Determinants of Exercise Performance: Evidence from Transgenic and Null Mouse Models **2010**, 185-194		
234	Current Proteome Profiling Methods **2010**, 46-57		
233	Glucocorticoid efficacy in asthma: is improved tissue remodeling upstream of anti-inflammation. *Journal of Investigative Medicine*, **2010**, 58, 19-22	2.9	18
232	Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. *PLoS ONE*, **2010**, 5, e8976	3.7	16
231	Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy. *PLoS ONE*, **2010**, 5, e11220	3.7	35
230	A Primer on Systems Biology, as Applied to Exercise Physiology and Metabolism **2010**, 307-318		
229	Systems Biology Through Time Series Data A Strength of Muscle Remodeling **2010**, 319-329		
228	Role of Genetics Factors in Sport Performance: Evidence from Family Studies **2010**, 90-100		1
227	Twin Studies in Sport Performance **2010**, 101-109		1
226	Selection Experiments in Rodents to Define the Complexity and Diversity of Endurance Capacity **2010**, 133-147		1
225	Genes and Endurance Performance **2010**, 149-158		

224	Mitochondrial DNA Sequence Variation and Performance **2010**, 215-226		
223	Genes, Exercise, and Cardiovascular Phenotypes **2010**, 249-261		
222	Genes, Exercise, and Protein Metabolism **2010**, 262-282		
221	Search for Genes Influencing Complex Traits **2010**, 70-78		
220	Proteomics in Exercise Training Research **2010**, 330-342		
219	The Regulation of Physical Activity by Genetic Mechanisms: Is there a Drive to be Active? **2010**, 283-293		2
218	CCL2 and CCR2 polymorphisms are associated with markers of exercise-induced skeletal muscle damage. *Journal of Applied Physiology*, **2010**, 108, 1651-8	3.7	51
217	Forty-eight hours of unloading and 24 h of reloading lead to changes in global gene expression patterns related to ubiquitination and oxidative stress in humans. *Journal of Applied Physiology*, **2010**, 109, 1404-15	3.7	58
216	PCB congener specific oxidative stress response by microarray analysis using human liver cell line. *Environment International*, **2010**, 36, 907-17	12.9	33
215	Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. *American Journal of Pathology*, **2010**, 176, 2891-900	5.8	113
214	The Influence of Physical Exercise on Adult Stem Cells **2010**, 343-349		
213	CCL2 and CCR2 variants are associated with skeletal muscle strength and change in strength with resistance training. *Journal of Applied Physiology*, **2010**, 109, 1779-85	3.7	30
212	Genes, Exercise, and Lipid Metabolism **2010**, 227-239		
211	The Human Genome and Epigenome **2010**, 1-13		
210	Ethnic Differences in Sport Performance **2010**, 121-132		2
209	Genes and Response to Training **2010**, 177-184		1
208	Genes, Exercise, and Glucose and Insulin Metabolism **2010**, 240-248		
207	The ACE Gene and Performance **2010**, 195-203		1

206	Twin and Family Studies of Training Responses **2010**, 110-120		1
205	Genes and Strength and Power Phenotypes **2010**, 159-176		
204	Genetic Epidemiology, Physical Activity, and Inactivity **2010**, 79-89		1
203	The ACTN3 Gene and Human Performance **2010**, 204-214		3
202	A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis. *Molecular Medicine*, **2010**, 16, 455-64	6.2	63
201	Genes, Exercise, and Psychological Factors **2010**, 294-305		4
200	Mitochondrial Medicine in Health and Disease: Interface Between Athletic Performance and Therapeutics **2010**, 14-32		1
199	Genetics and Ethics in Elite Sport **2010**, 351-361		2
198	Genes and Talent Selection **2010**, 362-372		
197	Performance Enhancement by Gene Doping **2010**, 373-382		
196	Bioethical Concerns in a Culture of Human Enhancement **2010**, 383-392		
195	Bioinformatics and Public Access Resources **2010**, 58-69		
194	A polymorphism near IGF1 is associated with body composition and muscle function in women from the Health, Aging, and Body Composition Study. *European Journal of Applied Physiology*, **2010**, 110, 315-24	3.4	18
193	Functional characterization of a haplotype in the AKT1 gene associated with glucose homeostasis and metabolic syndrome. *Human Genetics*, **2010**, 128, 635-45	6.3	11
192	Limb-girdle and congenital muscular dystrophies: current diagnostics, management, and emerging technologies. *Current Neurology and Neuroscience Reports*, **2010**, 10, 267-76	6.6	35
191	Knowledge-guided gene ranking by coordinative component analysis. *BMC Bioinformatics*, **2010**, 11, 162	3.6	6
190	Skeletal muscle gene expression in response to resistance exercise: sex specific regulation. *BMC Genomics*, **2010**, 11, 659	4.5	71
189	Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. *PLoS ONE*, **2010**, 5, e12981	3.7	28

188	Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. *Journal of Clinical Investigation*, **2009**, 119, 1583-94	15.9	199
187	A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. *Archives of Neurology*, **2009**, 66, 32-8		54
186	Gene expression and muscle fiber function in a porcine ICU model. *Physiological Genomics*, **2009**, 39, 141-50	3.9	40
185	Differential dependency network analysis to identify condition-specific topological changes in biological networks. *Bioinformatics*, **2009**, 25, 526-32	7.2	97
184	CNTF 1357 G -> A polymorphism and the muscle strength response to resistance training. *Journal of Applied Physiology*, **2009**, 107, 1235-40	3.7	23
183	Somatic mosaicism for Duchenne dystrophy: evidence for genetic normalization mitigating muscle symptoms. *American Journal of Medical Genetics, Part A*, **2009**, 149A, 1499-503	2.5	16
182	Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. *Annals of Neurology*, **2009**, 65, 667-76	9.4	324
181	Differences in fat and muscle mass associated with a functional human polymorphism in a post-transcriptional BMP2 gene regulatory element. *Journal of Cellular Biochemistry*, **2009**, 107, 1073-82	4.7	29
180	Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. *Muscle and Nerve*, **2009**, 39, 591-602	3.4	129
179	In vitro analysis of metabolites from the untreated tissue of Torpedo californica electric organ by mid-infrared laser ablation electrospray ionization mass spectrometry. *Metabolomics*, **2009**, 5, 263-276	4.7	41
178	A robust in vitro screening assay to identify NF-kappaB inhibitors for inflammatory muscle diseases. *International Immunopharmacology*, **2009**, 9, 1209-14	5.8	26
177	Proteomic profiling of glucocorticoid-exposed myogenic cells: Time series assessment of protein translocation and transcription of inactive mRNAs. *Proteome Science*, **2009**, 7, 26	2.6	8
176	GeneShelf: a web-based visual interface for large gene expression time-series data repositories. *IEEE Transactions on Visualization and Computer Graphics*, **2009**, 15, 905-12	4	9
175	Investigation of gene expression in C(2)C(12) myotubes following simvastatin application and mechanical strain. *Journal of Atherosclerosis and Thrombosis*, **2009**, 16, 21-9	4	17
174	Association of age with muscle size and strength before and after short-term resistance training in young adults. *Journal of Strength and Conditioning Research*, **2009**, 23, 1915-20	3.2	9
173	Delineation of a gene network underlying the pulmonary response to oxidative stress in asthma. *Journal of Investigative Medicine*, **2009**, 57, 756-64	2.9	13
172	Myostatin and follistatin polymorphisms interact with muscle phenotypes and ethnicity. *Medicine and Science in Sports and Exercise*, **2009**, 41, 1063-71	1.2	40
171	Strength, Size, and Muscle Quality in the Upper Arm following Unilateral Training in Younger and Older Males and Females. *Clinical Medicine: Arthritis and Musculoskeletal Disorders*, **2009**, 2, CMAMD.S1180		2

170	PCB Exposure In Vitro (PBMC): Differential Gene Expression, Pathway Analysis for Possible Mode(s) of Actions, and Disease Development in Comparison with PCB-Exposed Slovak Population. *Epidemiology*, **2009**, 20, S130	3.1	2
169	The Genomic Basis of Neuromuscular Disorders **2009**, 1265-1281		
168	caBIG VISDA: modeling, visualization, and discovery for cluster analysis of genomic data. *BMC Bioinformatics*, **2008**, 9, 383	3.6	11
167	Knowledge-guided multi-scale independent component analysis for biomarker identification. *BMC Bioinformatics*, **2008**, 9, 416	3.6	20
166	Motif-directed network component analysis for regulatory network inference. *BMC Bioinformatics*, **2008**, 9 Suppl 1, S21	3.6	17
165	Time series proteome profiling to study endoplasmic reticulum stress response. *Journal of Proteome Research*, **2008**, 7, 2435-44	5.6	34
164	Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. *Neuromuscular Disorders*, **2008**, 18, 371-81	2.9	114
163	CYP1A1 and MT1K are congener specific biomarker genes for liver diseases induced by PCBs. *Environmental Toxicology and Pharmacology*, **2008**, 25, 218-21	5.8	13
162	Interleukin-15 and interleukin-15R alpha SNPs and associations with muscle, bone, and predictors of the metabolic syndrome. *Cytokine*, **2008**, 43, 45-53	4	56
161	Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. *Developmental Cell*, **2008**, 14, 661-73	10.2	609
160	Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. *American Journal of Pathology*, **2008**, 172, 774-85	5.8	96
159	Dysferlin deficiency shows compensatory induction of Rab27A/Slp2a that may contribute to inflammatory onset. *American Journal of Pathology*, **2008**, 173, 1476-87	5.8	34
158	Mathematical modeling of corticosteroid pharmacogenomics in rat muscle following acute and chronic methylprednisolone dosing. *Molecular Pharmaceutics*, **2008**, 5, 328-39	5.6	20
157	Relationships between circadian rhythms and modulation of gene expression by glucocorticoids in skeletal muscle. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2008**, 295, R1031-47	3.2	54
156	INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men. *BMC Medical Genetics*, **2008**, 9, 117	2.1	16
155	Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. *Human Mutation*, **2008**, 29, 728-37	4.7	55
154	Transcriptional Cascades in Muscle Regeneration **2008**, 85-106		2
153	Biomarker Identification by Knowledge-Driven Multi-Level ICA and Motif Analysis **2007**,		1

152	PPARalpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. *BMC Medical Genetics*, **2007**, 8, 55	2.1	33
151	The proteome survey of an electricity-generating organ (Torpedo californica electric organ). *Proteomics*, **2007**, 7, 617-627	4.8	16
150	Resistin polymorphisms are associated with muscle, bone, and fat phenotypes in white men and women. *Obesity*, **2007**, 15, 392-402	8	27
149	Genetic medicine and the muscular dystrophies: triumphs and tribulations. *Developmental Medicine and Child Neurology*, **2007**, 44, 136-140	3.3	
148	Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens. *Physiological Genomics*, **2007**, 30, 282-99	3.6	49
147	Proteomics and systems biology in exercise and sport sciences research. *Exercise and Sport Sciences Reviews*, **2007**, 35, 5-11	6.7	15
146	Skipping toward personalized molecular medicine. *New England Journal of Medicine*, **2007**, 357, 2719-22	59.2	52
145	Gene selection for multiclass prediction by weighted Fisher criterion. *Eurasip Journal on Bioinformatics and Systems Biology*, **2007**, 64628		8
144	IGF-II gene region polymorphisms related to exertional muscle damage. *Journal of Applied Physiology*, **2007**, 102, 1815-23	3.7	46
143	Subcutaneous fat alterations resulting from an upper-body resistance training program. *Medicine and Science in Sports and Exercise*, **2007**, 39, 1177-85	1.2	17
142	Allometric scaling of biceps strength before and after resistance training in men. *Medicine and Science in Sports and Exercise*, **2007**, 39, 1013-9	1.2	8
141	The muscle strength and size response to upper arm, unilateral resistance training among adults who are overweight and obese. *Journal of Strength and Conditioning Research*, **2007**, 21, 307-13	3.2	24
140	Platelet Granzyme B expression is increased in sepsis: a potential mechanism for sepsis-associated endothelial apoptosis. *FASEB Journal*, **2007**, 21, A1125	0.9	1
139	Elucidating the Role of SNPs in AKT1 Gene Expression. *FASEB Journal*, **2007**, 21, A1152	0.9	
138	Functional recovery of glycine receptors in spastic murine model of startle disease. *Neurobiology of Disease*, **2006**, 21, 291-304	7.5	15
137	Probe set algorithms: is there a rational best bet?. *BMC Bioinformatics*, **2006**, 7, 395	3.6	64
136	Sexual dimorphism in immune response genes as a function of puberty. *BMC Immunology*, **2006**, 7, 2	3.7	77
135	Expression of two temporally distinct microglia-related gene clusters after spinal cord injury. *Glia*, **2006**, 53, 420-33	9	68

134	Automated sequence screening of the entire dystrophin cDNA in Duchenne dystrophy: point mutation detection. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2006**, 141B, 44-50	3.5	16
133	Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. *Journal of Biological Chemistry*, **2006**, 281, 429-38	5.4	73
132	Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. *Brain*, **2006**, 129, 996-1013	11.2	250
131	An interactive power analysis tool for microarray hypothesis testing and generation. *Bioinformatics*, **2006**, 22, 808-14	7.2	109
130	Loss of emerin at the nuclear envelope disrupts the Rb1/E2F and MyoD pathways during muscle regeneration. *Human Molecular Genetics*, **2006**, 15, 637-51	5.6	186
129	Endothelial cell activation and neovascularization are prominent in dermatomyositis. *Journal of Autoimmune Diseases*, **2006**, 3, 2		62
128	Translating mighty mice into neuromuscular therapeutics: is bigger muscle better?. *American Journal of Pathology*, **2006**, 168, 1775-8	5.8	9
127	ACE ID genotype and the muscle strength and size response to unilateral resistance training. *Medicine and Science in Sports and Exercise*, **2006**, 38, 1074-81	1.2	74
126	GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle. *Physiological Genomics*, **2006**, 27, 114-21	3.6	98
125	Muscular Dystrophies **2006**, 1080-1087		
124	Skeletal muscle remodeling during hypertrophy involves the coordinated expression of growth and atrophy genes. *FASEB Journal*, **2006**, 20, A392	0.9	
123	Prednisolone-induced changes in dystrophic skeletal muscle. *FASEB Journal*, **2005**, 19, 834-6	0.9	57
122	NKG2A and CD56 are coexpressed on activated TH2 but not TH1 lymphocytes. *Human Immunology*, **2005**, 66, 1223-34	2.3	8
121	Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. *Cell Metabolism*, **2005**, 2, 251-61	24.6	298
120	Proteome analysis of skeletal muscle from obese and morbidly obese women. *Diabetes*, **2005**, 54, 1283-8	0.9	78
119	Definition of the unique human extraocular muscle allotype by expression profiling. *Physiological Genomics*, **2005**, 22, 283-91	3.6	70
118	Intracellular expression profiling by laser capture microdissection: three novel components of the neuromuscular junction. *Physiological Genomics*, **2005**, 21, 70-80	3.6	28
117	ACTN3 and MLCK genotype associations with exertional muscle damage. *Journal of Applied Physiology*, **2005**, 99, 564-9	3.7	151

116	Multiple-laboratory comparison of microarray platforms. *Nature Methods*, **2005**, 2, 345-50	21.6	716
115	Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. *Arthritis and Rheumatism*, **2005**, 52, 1824-35		261
114	Exercise training increases electron and substrate shuttling proteins in muscle of overweight men and women with the metabolic syndrome. *Journal of Applied Physiology*, **2005**, 98, 168-79	3.7	42
113	Neuronal plasticity after spinal cord injury: identification of a gene cluster driving neurite outgrowth. *FASEB Journal*, **2005**, 19, 153-4	0.9	69
112	Decreased asialotransferrin in cerebrospinal fluid of patients with childhood-onset ataxia and central nervous system hypomyelination/vanishing white matter disease. *Clinical Chemistry*, **2005**, 51, 2031-42	5.5	40
111	Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 2560-6	9.4	109
110	ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. *Journal of Applied Physiology*, **2005**, 99, 154-63	3.7	223
109	Genotype Associations With Increases In Blood Creatine Kinase And Myoglobin Following Intense Eccentric Exercise. *Medicine and Science in Sports and Exercise*, **2005**, 37, S166???S167	1.2	73
108	Variability in muscle size and strength gain after unilateral resistance training. *Medicine and Science in Sports and Exercise*, **2005**, 37, 964-72	1.2	209
107	The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. *Nucleic Acids Research*, **2004**, 32, D578-81	20.1	40
106	Murine cytomegalovirus infection increases aortic expression of proatherosclerotic genes. *Circulation*, **2004**, 109, 893-7	16.7	32
105	Functional polymorphisms associated with human muscle size and strength. *Medicine and Science in Sports and Exercise*, **2004**, 36, 1132-9	1.2	56
104	Interactively optimizing signal-to-noise ratios in expression profiling: project-specific algorithm selection and detection p-value weighting in Affymetrix microarrays. *Bioinformatics*, **2004**, 20, 2534-44	7.2	106
103	Constitutive activation of MAPK cascade in acute quadriplegic myopathy. *Annals of Neurology*, **2004** , 55, 195-206	9.4	104
102	Embryonic myogenesis pathways in muscle regeneration. *Developmental Dynamics*, **2004**, 229, 380-92	2.9	158
101	Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. *Developmental Cell*, **2004**, 6, 673-84	10.2	194
100	Genetic Modifiers of Cerebrovascular Large Vessel Stenosis in Sickle Cell Anemia.. *Blood*, **2004**, 104, 1658-1658	2.1	1
99	Microarray Analysis of Peripheral Blood Monocytes in Sickle Cell Anemia Patients with Cerebrovascular Stenosis.. *Blood*, **2004**, 104, 3570-3570	2.2	

98	Decreased Platelet Expression of MYL9 (Myosin Regulatory Light Chain Polypeptide) and Other Genes with Platelets Dysfunction and CBFA2 Mutation: Insights from Platelet Expression Profiling.. *Blood*, **2004**, 104, 737-737	2.2	
97	Novel Genetic Variation in Muscle Genes Correlated with Muscle Strength, Size and Response to Resistance Training (FAMuSS). *Medicine and Science in Sports and Exercise*, **2004**, 36, S260	1.2	1
96	Patterns of global gene expression in rat skeletal muscle during unloading and low-intensity ambulatory activity. *Physiological Genomics*, **2003**, 13, 157-67	3.6	76
95	Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 1027-35	10.2	430
94	New molecular research technologies in the study of muscle disease. *Current Opinion in Rheumatology*, **2003**, 15, 698-707	5.3	8
93	Gene profiling in spinal cord injury shows role of cell cycle in neuronal death. *Annals of Neurology*, **2003**, 53, 454-68	9.4	226
92	In vivo filtering of in vitro expression data reveals MyoD targets. *Comptes Rendus - Biologies*, **2003**, 326, 1049-65	1.4	34
91	Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. *Molecular Cell*, **2003**, 12, 51-62	17.6	511
90	Expression profiling and pharmacogenomics of muscle and muscle disease. *Current Opinion in Pharmacology*, **2003**, 3, 309-16	5.1	8
89	Molecular responses of human muscle to eccentric exercise. *Journal of Applied Physiology*, **2003**, 95, 2485-94	3.7	103
88	Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome. *Journal of Physiology*, **2003**, 548, 401-10	3.9	43
87	Functional characteristics of dystrophic skeletal muscle: insights from animal models. *Journal of Applied Physiology*, **2002**, 93, 407-17	3.7	86
86	Development and production of an oligonucleotide MuscleChip: use for validation of ambiguous ESTs. *BMC Bioinformatics*, **2002**, 3, 33	3.6	6
85	Sources of variability and effect of experimental approach on expression profiling data interpretation. *BMC Bioinformatics*, **2002**, 3, 4	3.6	138
84	Response of rat muscle to acute resistance exercise defined by transcriptional and translational profiling. *Journal of Physiology*, **2002**, 545, 27-41	3.9	116
83	Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. *Journal of Immunology*, **2002**, 168, 4154-63	5.3	195
82	Slug is a novel downstream target of MyoD. Temporal profiling in muscle regeneration. *Journal of Biological Chemistry*, **2002**, 277, 30091-101	5.4	85
81	Expression profiling reveals metabolic and structural components of extraocular muscles. *Physiological Genomics*, **2002**, 9, 71-84	3.6	86

80	Integrin alpha 7 beta 1 in muscular dystrophy/myopathy of unknown etiology. *American Journal of Pathology*, **2002**, 160, 2135-43	5.8	57
79	A web-accessible complete transcriptome of normal human and DMD muscle. *Neuromuscular Disorders*, **2002**, 12 Suppl 1, S125-41	2.9	139
78	Collaborative translational research leading to multicenter clinical trials in Duchenne muscular dystrophy: the Cooperative International Neuromuscular Research Group (CINRG). *Neuromuscular Disorders*, **2002**, 12 Suppl 1, S147-154	2.9	10
77	Clarifying the boundaries between the inflammatory and dystrophic myopathies: insights from molecular diagnostics and microarrays. *Rheumatic Disease Clinics of North America*, **2002**, 28, 743-57	2.4	42
76	Genetic medicine and the muscular dystrophies: triumphs and tribulations. *Developmental Medicine and Child Neurology*, **2002**, 44, 136-40	3.3	
75	Confocal analysis of the dystrophin protein complex in muscular dystrophy. *Muscle and Nerve*, **2001**, 24, 262-72	3.4	16
74	Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. *Annals of Neurology*, **2001**, 49, 706-711	9.4	201
73	Molecular pathophysiology and targeted therapeutics for muscular dystrophy. *Trends in Pharmacological Sciences*, **2001**, 22, 465-70	13.2	61
72	Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy. *Neuromuscular Disorders*, **2001**, 11, 350-9	2.9	51
71	Molecular Diagnosis and Genetic Counseling of the Manifesting Carrier of Duchenne Muscular Dystrophy **2001**, 173-188		
70	Plasma membrane cytoskeleton of muscle: a fine structural analysis. *Microscopy Research and Technique*, **2000**, 48, 131-41	2.8	21
69	Private beta- and gamma-sarcoglycan gene mutations: evidence of a founder effect in Northern Italy. *Human Mutation*, **2000**, 16, 13-7	4.7	16
68	Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. *Journal of Cell Biology*, **2000**, 151, 1321-36	7.3	414
67	Unique PABP2 mutations in Cajuns suggest multiple founders of oculopharyngeal muscular dystrophy in populations with French ancestry **1999**, 86, 477-481		19
66	Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. *Journal of Gene Medicine*, **1999**, 1, 280-9	3.5	62
65	Prenatal diagnosis in a family affected with beta-sarcoglycan muscular dystrophy. *Neuromuscular Disorders*, **1999**, 9, 323-5	2.9	3
64	Counting muscular dystrophies in the post-molecular census. *Journal of the Neurological Sciences*, **1999**, 164, 3-6	3.2	9
63	Muscular dystrophy: identification and use of genes for diagnostics and therapeutics. *Archives of Pathology and Laboratory Medicine*, **1999**, 123, 1050-2	5	14

62	Mutations in the integrin alpha7 gene cause congenital myopathy. *Nature Genetics*, **1998**, 19, 94-7	36.3	327
61	Muscle maturation: implications for gene therapy. *Trends in Molecular Medicine*, **1998**, 4, 214-20		35
60	A dystrophin missense mutation showing persistence of dystrophin and dystrophin-associated proteins yet a severe phenotype. *Annals of Neurology*, **1998**, 44, 971-6	9.4	37
59	Role of the nerve in determining fetal skeletal muscle phenotype. *Developmental Dynamics*, **1998**, 211, 177-90	2.9	36
58	Homozygous alpha-sarcoglycan mutation in two siblings: one asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient. *Muscle and Nerve*, **1998**, 21, 769-75	3.4	63
57	Molecular Basis of Neuromuscular Disease. *Physical Medicine and Rehabilitation Clinics of North America*, **1998**, 9, 49-81	2.3	12
56	Muscular Dystrophies **1998**, 859-863		
55	Mutations in the sarcoglycan genes in patients with myopathy. *New England Journal of Medicine*, **1997**, 336, 618-24	59.2	196
54	Mutations in the delta-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2). *Neurogenetics*, **1997**, 1, 49-58	3	48
53	Asymptomatic dystrophinopathy. *American Journal of Medical Genetics Part A*, **1997**, 69, 261-7		28
52	Recruitment of mast cells to muscle after mild damage. *Journal of the Neurological Sciences*, **1996**, 135, 10-7	3.2	45
51	alpha-Sarcoglycan (adhalin) deficiency: complete deficiency patients are 5% of childhood-onset dystrophin-normal muscular dystrophy and most partial deficiency patients do not have gene mutations. *Journal of the Neurological Sciences*, **1996**, 140, 30-9	3.2	31
50	Autosomal recessive muscular dystrophy and mutations of the sarcoglycan complex. *Neuromuscular Disorders*, **1996**, 6, 475-82	2.9	39
49	Clinical and histopathological features of abnormalities of the dystrophin-based membrane cytoskeleton. *Brain Pathology*, **1996**, 6, 49-61	6	31
48	Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy. *Annals of Neurology*, **1996**, 40, 782-91	9.4	105
47	X-inactivation patterns in female Leber's hereditary optic neuropathy patients do not support a strong X-linked determinant. *American Journal of Medical Genetics Part A*, **1996**, 61, 356-62		32
46	Genetic counseling of isolated carriers of Duchenne muscular dystrophy. *American Journal of Medical Genetics Part A*, **1996**, 63, 573-80		24
45	Extensive genetic heterogeneity in the "pure" form of autosomal dominant familial spastic paraplegia (Str□mpell's disease). *Muscle and Nerve*, **1996**, 19, 1435-8	3.4	3

44	X-inactivation patterns in female Leber's hereditary optic neuropathy patients do not support a strong X-linked determinant **1996**, 61, 356		1
43	Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. *Nature Genetics*, **1995**, 11, 266-73	36.3	405
42	Voltage-gated ion channelopathies: inherited disorders caused by abnormal sodium, chloride, and calcium regulation in skeletal muscle. *Annual Review of Medicine*, **1995**, 46, 431-41	17.4	36
41	Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. *Pediatric Research*, **1995**, 37, 675-8	3.2	140
40	Phospholipase A2 activity in dystrophinopathies. *Neuromuscular Disorders*, **1995**, 5, 193-9	2.9	41
39	Overexcited or inactive: ion channels in muscle disease. *Cell*, **1995**, 80, 681-6	56.2	121
38	Hyperkalemic periodic paralysis with cardiac dysrhythmia: a novel sodium channel mutation?. *Annals of Neurology*, **1995**, 37, 408-11	9.4	16
37	Primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin. *Annals of Neurology*, **1995**, 38, 367-72	9.4	56
36	Molecular Diagnosis and Modern Management of Duchenne Muscular Dystrophy. *Neurologic Clinics*, **1994**, 12, 699-725	4.5	20
35	The rumpshaker mutation in spastic paraplegia. *Nature Genetics*, **1994**, 7, 351-2	36.3	142
34	A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. *Journal of the Neurological Sciences*, **1994**, 122, 44-56	3.2	94
33	Dystrophin-deficient myofibers are vulnerable to mast cell granule-induced necrosis. *Neuromuscular Disorders*, **1994**, 4, 325-33	2.9	53
32	Duchenne-Becker muscular dystrophy and the nondystrophic myotonias. Paradigms for loss of function and change of function of gene products. *Archives of Neurology*, **1993**, 50, 1227-37		23
31	RESPONSE TO LETTER BY LAW. *Cell Transplantation*, **1993**, 2, 438	4	
30	In utero fetal muscle biopsy for the diagnosis of Duchenne muscular dystrophy in a female fetus "suddenly at risk". *American Journal of Medical Genetics Part A*, **1993**, 46, 309-12		16
29	Genotype/phenotype correlations in Duchenne/Becker dystrophy. *Molecular and Cell Biology of Human Diseases Series*, **1993**, 3, 12-36		28
28	Dystrophin deficiency causes lethal muscle hypertrophy in cats. *Journal of the Neurological Sciences*, **1992**, 110, 149-59	3.2	104
27	Periodic paralysis in quarter horses: a sodium channel mutation disseminated by selective breeding. *Nature Genetics*, **1992**, 2, 144-7	36.3	173

26	X inactivation and dystrophin studies in a t(X;12) female: evidence for biochemical normalization in Duchenne muscular dystrophy carriers. *American Journal of Medical Genetics Part A*, **1992**, 43, 1012-5		16
25	Additional dystrophin fragment in Becker muscular dystrophy may result from proteolytic cleavage at deletion junctions. *American Journal of Medical Genetics Part A*, **1992**, 44, 378-81		9
24	A Met-to-Val mutation in the skeletal muscle Na+ channel alpha-subunit in hyperkalaemic periodic paralysis. *Nature*, **1991**, 354, 387-9	50.4	296
23	Muscle histology in Becker muscular dystrophy. *Muscle and Nerve*, **1991**, 14, 1067-73	3.4	22
22	Discordance of muscular dystrophy in monozygotic female twins: evidence supporting asymmetric splitting of the inner cell mass in a manifesting carrier of Duchenne dystrophy. *American Journal of Medical Genetics Part A*, **1991**, 40, 354-64		68
21	Is the carboxyl-terminus of dystrophin required for membrane association? A novel, severe case of Duchenne muscular dystrophy. *Annals of Neurology*, **1991**, 30, 605-10	9.4	86
20	Recent advances in dystrophin research. *Current Opinion in Neurobiology*, **1991**, 1, 420-9	7.6	22
19	In utero fetal muscle biopsy for the diagnosis of Duchenne muscular dystrophy. *American Journal of Obstetrics and Gynecology*, **1991**, 165, 728-32	6.4	38
18	Chapter 8 The Animal Models of Duchenne Muscular Dystrophy: Windows on the Pathophysiological Consequences of Dystrophin Deficiency. *Current Topics in Membranes*, **1991**, 113-154	2.2	40
17	Quadriceps myopathy: forme fruste of Becker muscular dystrophy. *Annals of Neurology*, **1990**, 28, 634-9	9.4	78
16	Duchenne and Becker Muscular Dystrophies: Genetics, Prenatal Diagnosis, and Future Prospects. *Clinics in Perinatology*, **1990**, 17, 845-863	2.8	21
15	Somatic reversion/suppression of the mouse mdx phenotype in vivo. *Journal of the Neurological Sciences*, **1990**, 99, 9-25	3.2	260
14	Human molecular genetics and the elucidation of the primary biochemical defect in Duchenne muscular dystrophy. *Cytoskeleton*, **1989**, 14, 163-8		5
13	Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. *Neuron*, **1989**, 2, 1019-29	13.9	299
12	Immunoelectron microscopic localization of dystrophin in myofibres. *Nature*, **1988**, 333, 863-6	50.4	427
11	The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. *Nature*, **1988**, 334, 154-6	50.4	349
10	Proteolytic fragment or new gene product?. *Nature*, **1988**, 336, 210	50.4	12
9	Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. *New England Journal of Medicine*, **1988**, 318, 1363-8	59.2	801

8	Molecular biology of Duchenne muscular dystrophy. *Trends in Neurosciences*, **1988**, 11, 480-4	13.3	21
7	Cell and fiber-type distribution of dystrophin. *Neuron*, **1988**, 1, 411-20	13.9	193
6	Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. *Cell*, **1988**, 54, 447-52	56.2	552
5	Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell*, **1987**, 51, 919-28	56.2	3732
4	Regional localization of the murine Duchenne muscular dystrophy gene on the mouse X chromosome. *Somatic Cell and Molecular Genetics*, **1987**, 13, 671-8		38
3	Subcellular fractionation of dystrophin to the triads of skeletal muscle. *Nature*, **1987**, 330, 754-8	50.4	286
2	Integrated Identification of Disease Specific Pathways Using Multi-omics data		1
1	A new long-read RNA-seq analysis approach identifies and quantifies novel transcripts of very large genes		1